Does Fallon Community Health Plan (FCHP) Cover Forteo?

What Is Forteo and Why Does Coverage Get Complicated?

Forteo is the brand name for teriparatide, a recombinant human parathyroid hormone (1-34) fragment. Injected subcutaneously at 20 mcg daily, it stimulates new bone formation rather than merely slowing resorption. The FDA first approved Forteo in November 2002 for postmenopausal women with osteoporosis at high fracture risk, and the label was later expanded to include men with primary or hypogonadal osteoporosis and patients on long-term glucocorticoid therapy [1].

Coverage is complicated because Forteo sits on specialty drug tiers, where monthly costs without insurance can reach $2,800 to $3,500. That price point alone triggers most health plans, FCHP included, to require documentation that cheaper alternatives have been tried or are medically inappropriate.

The Clinical Rationale Insurers Use

The Fracture Prevention Trial (N=1,637) showed teriparatide 20 mcg/day reduced vertebral fractures by 65% and nonvertebral fragility fractures by 53% versus placebo over a median 19-month follow-up [2]. That evidence is strong. The issue is that alendronate 70 mg weekly costs roughly $10 to $25 per month generic and reduces vertebral fracture risk by approximately 47% in high-risk patients [3]. Insurers read those numbers and build step-therapy policies that start with bisphosphonates.

Why FCHP Specifically Requires Prior Authorization

FCHP is a regional Massachusetts-based health plan. Its drug coverage follows a formulary that is updated at minimum annually and reviewed by a Pharmacy and Therapeutics (P&T) committee. Specialty biologics and bone anabolic agents, including Forteo, sit in tiers that require advance approval. The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis designate teriparatide as a first-line option only for patients at "imminent fracture risk," defined as T-score below -3.0, prior hip or vertebral fracture, or multiple risk factors [4]. FCHP's PA criteria generally track that clinical framing.

FCHP Formulary Structure: Where Forteo Sits

FCHP offers several plan types, including commercial HMO and PPO plans, Medicare Advantage plans (Fallon Senior Plan), and MassHealth (Medicaid) managed care products. Formulary placement differs across these.

Commercial FCHP Plans

On most FCHP commercial formularies, Forteo falls into Tier 4 or Tier 5 (specialty). Copayments or coinsurance at these tiers can range from $100 to $350 per 28-day supply depending on your specific benefit design. Deductible accumulation rules also apply, meaning your first fills in a plan year may cost more.

Generic teriparatide products, including Teriparatide-trzp (marketed as Brixta by Alvogen) and other biosimilar-adjacent generics, may occupy a lower specialty tier, potentially reducing your cost share. Ask FCHP's member services or your pharmacist whether a generic teriparatide is preferred on your current plan year's formulary before filling brand Forteo.

Fallon Senior Plan (Medicare Advantage)

Medicare Advantage drug coverage follows CMS formulary rules. Under Medicare Part D, teriparatide is typically a specialty-tier drug requiring prior authorization and, in some plan designs, step therapy through bisphosphonates. The Medicare Prescription Payment Plan (M3P), which launched in 2025, allows Part D enrollees to spread out-of-pocket costs across the calendar year rather than paying large amounts upfront, which may help with Forteo's specialty-tier cost [5].

The 2025 Medicare Part D redesign also capped out-of-pocket drug costs at $2,000 annually, a change that significantly benefits patients on high-cost specialty medications like Forteo.

MassHealth (Medicaid) Through FCHP

MassHealth covers teriparatide under its pharmacy benefit with prior authorization. Massachusetts MassHealth pharmacy coverage policies are governed by the Office of Medicaid. Coverage criteria mirror clinical guidelines closely and typically require documented severe osteoporosis with a T-score at or below -2.5 combined with at least one fragility fracture, or documented bisphosphonate contraindication or intolerance.

Prior Authorization Criteria: What FCHP Typically Requires

Prior authorization for Forteo through FCHP is not just a rubber-stamp process. Your prescribing clinician will need to submit documentation addressing several specific points.

Diagnosis and Bone Density Criteria

Most FCHP PA requests for teriparatide require:

• A confirmed diagnosis of osteoporosis based on DXA scan showing T-score <-2.5 at the lumbar spine, total hip, or femoral neck, OR
• A documented low-trauma (fragility) fracture in the spine, hip, wrist, or other site, OR
• T-score between -1.0 and -2.5 (osteopenia range) with at least two additional major clinical risk factors, as defined by FRAX 10-year fracture probability exceeding 20% for major osteoporotic fracture or 3% for hip fracture [6]

The FRAX tool, developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases at the University of Sheffield, provides the 10-year probability estimates used by most clinicians [6].

Step Therapy: Bisphosphonate Trial Requirement

FCHP, like most commercial plans, applies step therapy. This means a member generally must have tried and either failed to respond adequately to, or experienced a documented intolerance of, at least one bisphosphonate (typically alendronate or risedronate) before Forteo is approved.

"Failed to respond" in clinical terms means continued fracture occurrence or continued significant bone loss (decline in DXA T-score) despite at least 12 months of bisphosphonate therapy at an appropriate dose. "Intolerance" means documented adverse effects such as esophageal irritation, atypical femur fracture (AFF), osteonecrosis of the jaw (ONJ), or a medical contraindication such as renal impairment with GFR <35 mL/min/1.73 m².

Exceptions to Step Therapy

Step therapy exceptions exist under Massachusetts law. If your physician documents a medical reason why bisphosphonates are contraindicated or would likely cause harm, FCHP must consider waiving the step therapy requirement. Massachusetts General Laws Chapter 176O, Section 19 requires insurers operating in the state to have an exceptions process for step therapy when clinical circumstances justify it.

Duration of Coverage

The FDA label for Forteo specifies a lifetime limit of 24 months of use. FCHP's authorization periods typically run 6 to 12 months, requiring renewal documentation showing ongoing clinical necessity. Physicians must resubmit evidence of treatment response (usually a DXA scan showing stability or improvement) at each renewal.

How to Submit a Prior Authorization for Forteo Through FCHP

The prior authorization process involves your prescribing clinician, FCHP, and sometimes a specialty pharmacy. Here is the typical sequence.

Step 1: Clinician Submits PA Request

Your rheumatologist, endocrinologist, or primary care physician submits a PA form to FCHP. The form requires:

• ICD-10 diagnosis code (M80.xx for osteoporosis with fracture or M81.xx for osteoporosis without fracture)
• DXA results with T-scores
• Fracture history with imaging confirmation if available
• Documentation of prior bisphosphonate use: drug name, dose, duration, outcome
• Reason teriparatide is indicated over continued or alternative therapy

Step 2: FCHP Reviews the Request

FCHP's pharmacy team reviews the submission against their clinical criteria. Under Massachusetts law, plans must respond to urgent PA requests within 72 hours and non-urgent requests within 14 calendar days. Most Forteo requests are treated as non-urgent unless the patient has suffered a recent acute fracture.

Step 3: Approval, Denial, or Peer-to-Peer Review

If the initial submission is incomplete or the criteria are not clearly met, FCHP may issue a denial or request a peer-to-peer call. A peer-to-peer review allows your prescribing physician to speak directly with FCHP's medical director or reviewing physician to clarify clinical details. Many initially denied PA requests are overturned at this stage.

Step 4: Pharmacy Dispensing

Approved Forteo prescriptions are typically filled through a designated specialty pharmacy. FCHP contracts with specific specialty pharmacies for these medications. Your physician's office or FCHP member services can tell you which specialty pharmacies are in-network for your plan.

What If FCHP Denies Coverage for Forteo?

A denial is not the end of the road. Several formal pathways exist.

Internal Appeal

You or your physician can file a formal internal appeal with FCHP within 30 days of receiving a denial notice (Massachusetts law may extend this timeframe in certain circumstances). Submit additional clinical documentation: updated DXA results, peer-reviewed literature supporting teriparatide use in your specific clinical scenario, and a detailed letter of medical necessity from your physician.

The AACE/ACE position statement on osteoporosis pharmacotherapy states: "Anabolic therapy should be considered as initial treatment in patients presenting with very high fracture risk, including those with multiple vertebral fractures or very low bone mineral density" [4]. That language can be cited directly in an appeal letter.

External Review

If FCHP upholds its denial after an internal appeal, Massachusetts law gives you the right to an independent external review conducted by a state-certified independent review organization (IRO). The IRO's decision is binding on FCHP.

State Insurance Division Complaint

The Massachusetts Division of Insurance oversees FCHP. Filing a complaint with the Division can prompt the insurer to re-examine a case, particularly when step therapy exceptions under state law appear to have been ignored.

Cost-Saving Options If Prior Authorization Is Approved

Even with coverage, specialty-tier cost share can be substantial. Several programs may reduce your out-of-pocket costs.

Eli Lilly's Forteo Savings Program

Eli Lilly offers a savings card program for commercially insured patients (not applicable to Medicare or Medicaid). Eligible patients may pay as little as $0 to $25 per month for Forteo. Check the current terms at Eli Lilly's official patient assistance site, as program details change periodically.

Patient Assistance Programs (PAP)

Uninsured patients or those who do not qualify for the savings card may apply for Lilly's Lilly Cares Foundation patient assistance program. Eligibility is income-based.

Generic Teriparatide

Ask your physician whether a generic teriparatide (Teriparatide-trzp / Brixta) is an acceptable substitution. The FDA approved the first teriparatide generic in 2019 [7]. Generics carry the same 20 mcg/day dose and delivery device but typically appear on a lower formulary tier, reducing your cost share even if the drug itself is considered a specialty agent.

Clinical Alternatives to Forteo That FCHP May Cover at Lower Tiers

If Forteo coverage is denied or cost is prohibitive even with assistance programs, several alternative osteoporosis therapies may be appropriate depending on your clinical profile.

Bisphosphonates (First-Line, Generic)

Alendronate 70 mg weekly and risedronate 35 mg weekly are generic, inexpensive, and well-tolerated by most patients. The FIT trial (N=2,027) showed alendronate reduced hip fracture risk by 51% in women with pre-existing vertebral fractures [3]. These are the medications step therapy policies start with.

Denosumab (Prolia)

Prolia (denosumab 60 mg subcutaneous injection every 6 months) is a RANK-L inhibitor that reduces bone resorption. The FREEDOM trial (N=7,808) showed denosumab reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months [8]. Prolia typically sits on a lower specialty tier than Forteo on FCHP formularies, though it also requires prior authorization.

Denosumab requires continuous use: stopping it without transitioning to a bisphosphonate causes a rebound increase in bone resorption and raises fracture risk [9].

Romosozumab (Evenity)

Evenity (romosozumab-aqqg 210 mg/month subcutaneous, given as two 105-mg injections) works by both stimulating bone formation and reducing resorption. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced hip fracture risk by 38% versus alendronate alone over 24 months [10]. Evenity carries an FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death, limiting its use in patients with recent cardiovascular events.

Abaloparatide (Tymlos)

Tymlos (abaloparatide 80 mcg/day subcutaneous) is a PTHrP analogue with a mechanism similar to teriparatide. The ACTIVE trial (N=2,463) showed abaloparatide reduced new vertebral fractures by 86% versus placebo at 18 months [11]. Some FCHP plan formularies may place abaloparatide at a comparable or slightly lower tier than brand Forteo, making it a potential coverage alternative if Forteo is specifically denied.

Original HealthRX Clinical Decision Framework

The following framework is used by the HealthRX medical team to guide patients and prescribers when navigating Forteo coverage through regional health plans such as FCHP. It is not a substitute for individualized clinical judgment.

FCHP Forteo Coverage Navigation Framework (HealthRX)

1. Confirm PA criteria are fully documentable before submitting. Review DXA results, fracture history, and bisphosphonate trial records. An incomplete first submission delays approval by weeks and may create a denial record that complicates appeals.

2. If step therapy applies, document the bisphosphonate trial precisely. Record drug name, dose, start date, end date, and the specific outcome (fracture on therapy, T-score decline, or adverse event). Vague documentation is the most common reason PA requests fail.

3. Request peer-to-peer review immediately on any denial. Most physicians do not know this option exists. FCHP is required to make its reviewing physician available within a specified timeframe. A 10-minute call resolves many cases.

4. Check whether generic teriparatide is separately formulary-listed. If it is on a lower tier than brand Forteo, a generic prescription may be approved faster and at lower cost share.

5. Run FRAX scores and include the printout in the PA submission. A 10-year major osteoporotic fracture probability above 20% is a strong quantitative argument that meets evidence-based criteria for anabolic therapy.

6. If anabolic therapy is denied entirely, discuss romosozumab or abaloparatide as alternatives. Their PA criteria may differ from Forteo's, and one might be approachable through a different evidence pathway.

What Your Physician Needs to Document: A Clinical Checklist

Strong PA submissions for Forteo through FCHP include all of the following:

• Most recent DXA report with T-scores at the spine, total hip, and femoral neck
• FRAX 10-year fracture probability calculation
• List of prior osteoporosis medications: name, dose, duration, discontinuation reason
• Imaging reports for any fractures (X-ray, CT, or MRI confirmation)
• Current medication list showing any drugs that affect bone density (glucocorticoids, aromatase inhibitors, androgen deprivation therapy)
• Brief letter of medical necessity signed by the prescribing physician explaining why teriparatide is appropriate for this specific patient at this time
• Reference to AACE or National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) guidelines supporting anabolic therapy in high fracture-risk patients [4, 12]

The BHOF 2022 Clinical Practice Guideline states: "Pharmacologic treatment should be initiated in postmenopausal women and men age 50 and older presenting with hip or vertebral fractures, or with DXA T-score of -2.5 or below at the femoral neck, total hip, or lumbar spine" [12].

Monitoring Requirements During Teriparatide Therapy

FCHP may require documentation of monitoring at PA renewal. Clinically, patients on Forteo should have:

• DXA repeated at 12 to 24 months to assess bone mineral density response
• Calcium and vitamin D levels checked; adequate intake (1,000 to 1,200 mg calcium daily and 800 to 1,000 IU vitamin D3 daily) supports treatment response [12]
• Serum calcium assessed within 4 to 6 weeks of initiation given teriparatide's transient hypercalcemic effect
• Monitoring for orthostatic hypotension, particularly in the first several doses
• Assessment for urolithiasis symptoms given a modest increase in urinary calcium excretion

After completing the 24-month lifetime limit, patients must transition to antiresorptive therapy. Stopping teriparatide without starting a bisphosphonate or denosumab leads to rapid bone loss within 12 to 18 months. The BHOF and AACE guidelines both recommend transitioning to alendronate or denosumab after completing an anabolic course [4, 12].